Scinai Immunotherapeutics Ltd.’s Post

🌟 Columbus Venture Partners brings exciting news and updates about our portfolio companies! 🌟 🏆 Co-Founder and Chief Scientific Officer of Vivet Therapeutics, Gloria Gonzalez-Aseguinolaza has been honored with the prestigious Rosalind Franklin Society (RFS) Special Award in Science 🔬 for her remarkable contributions and dedication to advancing scientific knowledge. 🚀 Artax Biopharma Inc has updated information on their candidate pipeline and the progress they are making in the development of AX-158 and AX-194 for #autoimmunediseases, #psoriasis, and #atopicdermatitis. Learn more here: https://lnkd.in/d_RrncBp 💡 Integra Therapeutics will receive up to €10.5 million from the European Commission for their advanced therapies platform #FiCAT through the #eicAccelerator program. ℹ More information: https://lnkd.in/dB_WXPqD 🔬 QUATRE LAB explains the benefits of outsourcing to CROs for the bio-pharmaceutical industry, addressing the complexities of rare diseases more effectively and ensuring innovative treatments reach patients faster. 🔍 To read the full article, visit: https://lnkd.in/d4xbxmQc 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗮𝗹𝗹 𝗼𝗳 𝘆𝗼𝘂! #biotech #innovation #healthcare #pharmaceuticals #research #ColumbusVP #investment #AdvancedTherapies #GeneTherapy #GeneWriting #CRISPR #clinicaltrials #immunology

Check out the next in the series of Pharmaron DMPK webinars on October 29, this one on antibody-drug conjugates (ADCs)

Highlights from #MEDICA2024 🚀 #CentralBioHub had an incredible time at MEDICA 2024 in Düsseldorf, where we showcased the future of #biospecimen procurement! From November 11–14, our team had the privilege of engaging with researchers, pharmaceutical companies, and diagnostic labs from all over the world at Hall 03, Booth G60. We were excited to introduce visitors to Central BioHub’s revolutionary biospecimen marketplace. The positive feedback we received from booth visitors highlighted the speed, transparency, and simplicity of our platform - key features that distinguish us in the biospecimen procurement industry. The connections we made were invaluable, and we look forward to nurturing collaborations that will accelerate scientific discoveries. Stay tuned for more updates on upcoming events and innovations! Together, we will continue to advance research and diagnostics. 🔬 Explore our online marketplace and discover how we’re making biospecimen sourcing easier, faster, and more reliable than ever before. https://lnkd.in/da52n63A #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine #Medica2024 #ResearchRevolution

Exclusive: In five short years, Duality Biologics has quickly become an antibody-drug conjugate powerhouse and linked up with multiple biopharmas like GSK, BeiGene and BioNTech en route to a potential HKEX listing. Now, it's Athena Countouriotis MD and her team at Avenzo Therapeutics' turn. They have secured another experimental medicine for their pipeline at Avenzo, this time getting Duality's EGFRxHER3 bispecific in the bustling ADC space. It's a niche area that Bristol Myers Squibb paid $800 million to get into about 12 months ago. For Avenzo, the new deal arrives shortly after it tapped VelaVigo and Allorion Therapeutics for other treatment candidates. #antibodydrugconjugate #adc #avenzo #dualitybio #chinabiotech #egfr #her3 #biotechdeal #biopharma #oncologydrugdevelopment

Thoughts on this? >> Regeneron and Genentech battle for ophthalmologists’ affinity in Eylea HD, Vabysmo matchup >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #productmarketing #healthcare

𝗕𝗶𝗴 𝗻𝗲𝘄𝘀 𝗳𝗿𝗼𝗺 𝗖𝗲𝗹𝗹𝘁𝗿𝗶𝗼𝗻! Alongside receiving a major U.S. FDA approval for Steqeyma, its biosimilar to Stelara, an autoimmune disease, Celltrion is making bold moves to expand its CDMO business. The company plans to invest heavily in enhancing production capabilities, signalling a strategic push to strengthen its presence in the global biotech manufacturing sector. This dual focus, delivering innovative treatments like Steqeyma and scaling up CDMO services positions Celltrion as a key player in advancing healthcare solutions and supporting other biotech innovators. This is a win for patients, offering more affordable options and potentially transforming lives worldwide. Full article in the comments! #HealthcareInnovation #Biosimilars #Pharma #Celltrion #FDAApproval

Thoughts on this? >> John Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet; Amylyx names commercial chief >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #productmarketing #biotech #pharmaceutical

Thoughts on this? >> Regeneron and Genentech battle for ophthalmologists’ affinity in Eylea HD, Vabysmo matchup >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #productmarketing #biotech

Get ready for SCOPE Europe Summit 2024! We’re excited to be attending the SCOPE 2024 in Barcelona and learn about the new updates in the clinical trial space. Catch up with our Chief Strategy Officer, Kristin Yakimow, on October 29 to discuss how real-world imaging datasets (RWiD) can help optimize clinical trials by improving patient selection, trial efficiency, and data-driven decision-making. Segmed’s fit-for-purpose Real world imaging datasets (RWiD) and multimodal longitudinal datasets are key to unlocking new possibilities for pharmaceutical and Biotech companies in accelerating drug development, improving clinical trial design, and driving innovation. To schedule a meeting and to understand more about Segmed - https://hubs.li/Q02VxgRm0 #SCOPE2024 #ClinicalTrials #RWiD #Innovation #Pharma #Biotech #CRO #DrugDevelopment #Segmed #RWD #imagingdata #realworldimagingdata

We’re celebrating a great achievement today! Eight organizations across the clinical trials industry have joined together as founding members of the Biospecimen Management Consortium. Hosted by Slope, the BMC will drive a variety of initiatives aimed at developing best practices and industry standards; streamlining biospecimen lifecycle operations and data management; and influencing regulatory policy. You can follow along with their journey @Biospecimen Management Consortium and read more about their goals at the link below.#BiospecimenConsortium #BiospecimenManagement #ClinicalTrials